Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 13/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23891536 | 0.87 | EP300 (0.44) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL23891679 | 0.87 | EP300 (0.44) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL31149069 | 0.85 | EP300 (0.42) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL17605990 | 0.85 | EP300 (0.42) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL17605847 | 0.85 | EP300 (0.43) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL17605989 | 0.85 | EP300 (0.42) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL17605850 | 0.85 | EP300 (0.43) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL22039701 | 0.85 | EP300 (0.42) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL22040127 | 0.85 | EP300 (0.43) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL17606368 | 0.83 | HCAR2 (0.52) | EP300CREBBPHCAR2CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016044770-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | EP300 5/4885CREBBP 154/4885HCAR2 748/4885 |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, KAT2A | EP300 6/4885CREBBP 153/4885HCAR2 711/4885 |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | EP300 5/4885CREBBP 154/4885HCAR2 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.